Utility of molecular alterations in myeloid diseases
| . | Gene . | Disease . | Drug . |
|---|---|---|---|
| Diagnosis | KITD816V | Mastocytosis | |
| JAK2; MPL; CALR; CSF3R | MPN/MDS | ||
| Prognosis | TP53 | Most | |
| NPM1; CEBPA; RUNX1; FLT3; ASXL1 | AML | ||
| SF3B1 | MDS | ||
| Therapeutic target | ABL1 | CML | Tyrosine kinase inhibitor |
| IDH1; IDH2; | AML | IDH inhibitor | |
| FLT3-ITD,TKD | AML | Midostaurin | |
| JAK2V617F | MPN | JAK2 inhibitor | |
| PML-RARA | APL | ATRA and ATO | |
| Other recurrent alterations with unclear clinical utility | TET2;DNMT3A; SRSF2; U2AF1; EZH2; ZRSR2; STAG 2; CBL; NRAS; SETBP1; ETV6; WT1; BCOR; BCORL1 | Myeloid neoplasms |
| . | Gene . | Disease . | Drug . |
|---|---|---|---|
| Diagnosis | KITD816V | Mastocytosis | |
| JAK2; MPL; CALR; CSF3R | MPN/MDS | ||
| Prognosis | TP53 | Most | |
| NPM1; CEBPA; RUNX1; FLT3; ASXL1 | AML | ||
| SF3B1 | MDS | ||
| Therapeutic target | ABL1 | CML | Tyrosine kinase inhibitor |
| IDH1; IDH2; | AML | IDH inhibitor | |
| FLT3-ITD,TKD | AML | Midostaurin | |
| JAK2V617F | MPN | JAK2 inhibitor | |
| PML-RARA | APL | ATRA and ATO | |
| Other recurrent alterations with unclear clinical utility | TET2;DNMT3A; SRSF2; U2AF1; EZH2; ZRSR2; STAG 2; CBL; NRAS; SETBP1; ETV6; WT1; BCOR; BCORL1 | Myeloid neoplasms |
ATO, arsenic trioxide; ATRA, all-trans retinoic acid.